Anzeige
Mehr »
Samstag, 26.07.2025 - Börsentäglich über 12.000 News
Richtig investiert verwandelt der Goldpreis jeden Euro in glänzendes Vermögen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
291 Leser
Artikel bewerten:
(1)

Primus Pharmaceuticals: Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus

SCOTTSDALE, ARIZONA / ACCESS Newswire / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated.

Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or "normal aging," while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility.

Widespread, Under-Recognized Health Threat

  • CVI, also known as chronic venous disease or venous reflux disease, impacts twice (2x) as many Americans as coronary heart disease, three times (3x) peripheral arterial disease, and 30 times (30x) the number of Americans who have a heart attack each year.

  • According to CDC, up to 900,000 Americans are affected by venous thromboembolism annually, and 60,000 to 100,000 people die each year.

  • Millions suffer daily challenges - standing, sitting, flying - due to blood pooling in the legs, worsened by inactivity or pressure.

  • Traditional treatments - leg elevation, compression stockings or surgical procedures - are often cumbersome, uncomfortable, underutilized, and may be expensive with added health risks.

Life-Changing Solution: Vasculera®

Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and:

  • Calms inflammation and oxidative stress

  • Strengthens weakened vein walls

  • Improves overall venous function

  • Counters localized CVI blood acidosis

Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo.

Expert Physician Perspectives

"CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity," said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. "Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition."

Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, "CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications."

Robust Clinical Backing

  • Over 60 published peer-reviewed clinical studies confirm diosmin's effectiveness in reducing leg pain, swelling, and skin deterioration associated with CVI.

  • Vascular medicine experts recommend Vasculera's ultra-micronized diosmin as the only U.S. product for venous ulcers and CVI symptoms, both as standalone and adjunctive therapy in national treatment guidelines.

Public Health Call to Action

With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to:

  • Proactively screen all at-risk patients for CVI

  • Integrate proven prescription metabolic therapies like Vasculera with CVI standards of care

For prescribing information, visit www.vasculera.com.

About Primus Pharmaceuticals

Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit www.primuxrx.com.

Contact Information

Randy Keating
Public Relations Manager
rkeating@primusrx.com
4802460509

.

SOURCE: Primus Pharmaceuticals



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/primus-sounds-alarm-on-chronic-venous-insufficiency-as-president-trum-1052767

© 2025 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.